Robert W. Baird downgrades Genzyme Corp. (Nasdaq: GENZ) from Outperform to Neutral with a $58 price target, saying the prognosis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE